Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2014

Politi Katerina, Gettinger Scott

Abstract excerpt

Mutations in ALK are a common mechanism of acquired resistance to small molecule ALK inhibitors in ALK-rearranged lung cancer. Different mutants exhibit differential sensitivity to ALK inhibitors. Matching the mutational profile of the tumor with the appropriate ALK inhibitor is likely to be important to maximize benefit for patients.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbazoles
Share to Drug Resistance, Neoplasm
Share to ALK gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Piperidines

Share to Protein Kinase Inhibitors

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 25228532
DOI: 10.1158/1078-0432.CCR-14-2306
PMCID: PMC4401422

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.PMID 25228532Read ↗

Targeting drug-resistant mutations in ALK.Semantic proximity Read ↗

Targeting ALK: Precision Medicine Takes on Drug Resistance.Semantic proximity Read ↗

Lung cancer: Resolving resistance to ALK-targeted therapy.Semantic proximity Read ↗

Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.Semantic proximity Read ↗

PI3Kβ inhibition restores ALK inhibitor sensitivity in ALK-rearranged lung cancerSemantic proximity Read ↗

Drug resistance in ALK-positiveNon-small cell lungcancer patientsSemantic proximity Read ↗

Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?Semantic proximity Read ↗

A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors.Semantic proximity Read ↗

Drugging the bad "AKT-TOR" to overcome TKI-resistant lung cancer.Semantic proximity Read ↗

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.Semantic proximity Read ↗

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.Semantic proximity Read ↗

Exploring three important drug resistance mutations in ALK with three different inhibitors: insight from molecular simulations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.